Precede Biosciences closed an $83.5–$84 million financing to expand its liquid biopsy platform focused on transcriptome‑level cancer profiling. The company said it will scale capacity to support partnerships with pharmaceutical companies and position its assay to inform patient selection, mechanism‑of‑response studies and companion diagnostic use across ADCs, radiopharmaceuticals and other modalities. Precede reported ongoing collaborations tied to roughly 30 drug programs and plans to increase lab throughput and regulatory readiness to meet pharma demand for longitudinal molecular monitoring during trials.